To determine whether there is a benefit for biochemical control with adjuvant radiation therapy to the surgical bed following radical prostatectomy in patients with seminal vesicle invasion and pathologically negative pelvic lymph nodes (pT3b-pT4 pN0).
Methods
We retrospectively reviewed the clinical records of radical prostatectomy patients treated between 1995 and 2002. A total of 66 patients with seminal vesicle invasion were identified: 45 of these patients received adjuvant radiation therapy and 21 were observed. Radiation therapy was initiated within 4 months of prostatectomy. Median dose was 66 Gy (range, 60–70 Gy). Median follow-up from the day of surgery was 40.6 months (mean, 41.5; range, 12–99). Biochemical recurrence was defined as the first value ≥0.2 ng/ml.
Results
At two years, the proportion of patients free from biochemical recurrence was 80% in patients who received adjuvant radiation therapy versus 54% for those not given radiation therapy (P = 0.036). Actuarial biochemical recurrence at 5 years was 59% vs 41% for the radiation therapy and no radiation therapy groups, respectively. On univariate Cox regression model, the hazard of biochemical failure was also associated with a detectable (≥0.2 ng/ml) postsurgical prostate-specific antigen (P = 0.02) prior to radiation therapy. Pathological T stage (pT3b vs pT4), Gleason score, primary Gleason pattern and positive surgical margins were not significantly associated with biochemical recurrence. The hazard of biochemical failure was around 85% lower in the radiation therapy group than in the observation group (P = 0.002).
Conclusions
Data from the present series suggest that adjuvant radiation therapy for patients with seminal vesicle invasion and undetectable (≤0.2 ng/ml) postoperative prostate-specific antigen significantly reduces the likelihood of biochemical failure.
EpsteinJ.I., CarmichaelM., WalshP.C.: Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis.J Urol, 149: 1040–1045, 1993.
2.
EpsteinJ.I., PartinA.W., PotterS.R., WalshP.C.: Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters.Urology, 56: 283–288, 2000.
3.
MukamelE., deKernionJ.B., HannahJ., SmithR.B., SkinnerD.G., GoodwinW.E.: The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate.Cancer, 59: 1535–1538, 1987.
4.
OhoriM., ScardinoP.T., LapinS.L., Seale-HawkinsC., LinkJ., WheelerT.M.: The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer.Am J Surg Pathol, 17: 1252–1261, 1993.
5.
VillersA.A., McNealJ.E., RedwineE.A., FreihaF.S., StameyT.A.: Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma.J Urol, 143: 1183–1187, 1990.
6.
BollaM., vanP.H., ColletteL., vanC.P., VekemansK., DaP.L., de ReijkeT.M., VerbaeysA., BossetJ.F., vanV.R., MarechalJ.M., ScallietP., HaustermansK., PierartM.: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).Lancet, 366: 572–578, 2005.
ValicentiR.K., GomellaL.G., PerezC.A.: Radiation therapy after radical prostatectomy: a review of the issues and options.Semin Radiat Oncol, 13: 130–140, 2003.
9.
VargasC., KestinL.L., WeedD.W., KraussD., ViciniF.A., MartinezA.A.: Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.Int J Radiat Oncol Biol Phys, 61: 714–724, 2005.
10.
ViciniF.A., ZiajaE.L., KestinL.L., BrabbinsD.S., StrombergJ.S., GonzalezJ.A., MartinezA.A.: Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.Urology, 54: 111–117, 1999.
11.
LeventisA.K., ShariatS.F., KattanM.W., ButlerE.B., WheelerT.M., SlawinK.M.: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy.J Clin Oncol, 19: 1030–1039, 2001.
12.
NudellD.M., GrossfeldG.D., WeinbergV.K., RoachM.III, CarrollP.R.: Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns.Urology, 54: 1049–1057, 1999.
13.
ParkerC., WardeP., CattonC.: Salvage radiotherapy for PSA failure after radical prostatectomy.Radiother Oncol, 61: 107–116, 2001.
14.
SchildS.E.: Radiation therapy after prostatectomy: now or later?Semin Radiat Oncol,8: 132–139, 1998.
15.
SchildS.E.: Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy.Int J Cancer, 96: 94–98, 2001.
16.
CadedduJ.A., PartinA.W., DeWeeseT.L., WalshP.C.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.J Urol, 159: 173–177, 1998.
17.
DjavanB., MoulJ.W., ZlottaA., RemziM., RaveryV.: PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.Eur Urol, 43: 12–27, 2003.
18.
EgawaS., MatsumotoK., SuyamaK., SohS., KuwaoS., IwamuraM.: Limited suppression of PSA after salvage radiotherapy for its isolated elevation after radical prostatectomy.Urology, 53: 148–154, 1999.
19.
HaabF., MeulemansA., Boccon-GibodL., DaugeM.C., DelmasV., HennequinC., BenbunanD., Boccon-GibodL.: Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay.Urology, 45: 1022–1027, 1995.
20.
TaylorN., KellyJ.F., KubanD.A., BabaianR.J., PistersL.L., PollackA.: Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.Int J Radiat Oncol Biol Phys, 56: 755–763, 2003.
21.
ValicentiR.K., GomellaL.G.: Durable efficacy of adjuvant radiation therapy for prostate cancer: will the benefit last?Semin Urol Oncol,18: 115–120, 2000.
22.
AnscherM.S.: Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate-specific antigen.Int J Cancer, 96: 91–93, 2001.
23.
AnscherM.S., ProsnitzL.R.: Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radiotherapy.Int J Radiat Oncol Biol Phys, 21: 941–947, 1991.
24.
JohnsonC.W., AnastasiadisA.G., McKiernanJ.M., SalomonL., EatonS., GoluboffE.T., OlssonC.A., BensonM.C.: Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles.Urol Oncol, 22: 107–111, 2004.
25.
AnscherM.S., ProsnitzL.R.: Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule.J Urol, 138: 1407–1412, 1987.
26.
LeeH.M., SolanM.J., LupinacciP., GomellaL.G., ValicentiR.K.: Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.Urology, 64: 84–89, 2004.
27.
ValicentiR.K., GomellaL.G., IsmailM., StrupS.E., MulhollandS.G., DickerA.P., PetersenR.O., NewschafferC.J.: The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis.Int J Radiat Oncol Biol Phys, 45: 53–58, 1999.
28.
CatalonaW.J., SmithD.S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.J Urol, 152: 1837–1842, 1994.
29.
D'amicoA.V., WhittingtonR., MalkowiczS.B., SchultzD., SchnallM., TomaszewskiJ.E., WeinA.: A multivariate analysis of clinical and pathological factors that predict for prostate-specific antigen failure after radical prostatectomy for prostate cancer.J Urol, 154: 131–138, 1995.
30.
MastersonT.A., PettusJ.A., MiddletonR.G., StephensonR.A.: Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status.Urology, 66: 152–155, 2005.
TefilliM.V., GheilerE.L., TiguertR., BanerjeeM., SakrW., GrignonD.J., PontesJ.E., WoodD.P.Jr..: Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer.J Urol, 160: 802–806, 1998.
33.
TrapassoJ.G., deKernionJ.B., SmithR.B., DoreyF.: The incidence and significance of detectable levels of serum prostate-specific antigen after radical prostatectomy.J Urol, 152: 1821–1825, 1994.
34.
ValicentiR.K., GomellaL.G., IsmailM., MullhollandS.G., PetersenR.O., CornB.W.: Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control.Cancer, 82: 1909–1914, 1998.
35.
BloomK.D., RichieJ.P., SchultzD., RenshawA., SaegaertT., D'amicoA.V.: Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.Urology, 63: 333–336, 2004.
36.
KamatA.M., BabaianK., CheungM.R., NayaY., HuangS.H., KubanD., BabaianR.J.: Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.J Urol, 170: 1860–1863, 2003.
37.
LeibovichB.C., EngenD.E., PattersonD.E., PisanskyT.M., AlexanderE.E., BluteM.L., BergstralhE.J., ZinckeH.: Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.J Urol, 163: 1178–1182, 2000.
38.
WuJ.J., KingS.C., MontanaG.S., McKinstryC.A., AnscherM.S.: The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.Int J Radiat Oncol Biol Phys, 32: 317–323, 1995.
39.
CoetzeeL.J., HarsV., PaulsonD.F.: Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.Urology, 47: 232–235, 1996.
SchildS.E., WongW.W., GradoG.L., HalyardM.Y., NovickiD.E., SwansonS.K., LarsonT.R., FerrigniR.G.: The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer.Int J Radiat Oncol Biol Phys, 34: 535–541, 1996.
43.
ZietmanA.L., CoenJ.J., ShipleyW.U., AlthausenA.F.: Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure.Urology, 42: 292–298, 1993.
44.
CattonC., GospodarowiczM., WardeP., PanzarellaT., CattonP., McLeanM., MilosevicM.: Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.Radiother Oncol, 59: 51–60, 2001.
45.
MorrisM.M., DallowK.C., ZietmanA.L., ParkJ., AlthausenA., HeneyN.M., ShipleyW.U.: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.Int J Radiat Oncol Biol Phys, 38: 731–736, 1997.
46.
CornB.W., WinterK., PilepichM.V.: Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85–31. Radiation Therapy Oncology Group.Urology, 54: 495–502, 1999.
47.
EulauS.M., TateD.J., StameyT.A., BagshawM.A., HancockS.L.: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.Int J Radiat Oncol Biol Phys, 41: 735–740, 1998.
48.
PetrovichZ., LieskovskyG., LangholzB., LuxtonG., JozsefG., SkinnerD.G.: Radiotherapy following radical prostatectomy in patients with adenocarcinoma of the prostate.Int J Radiat Oncol Biol Phys, 21: 949–954, 1991.
